Reaction equation
[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N+:5]#[C-:6])[CH3:3].O.O.C([O-])(=O)CC(CC([O-])=O)(C([O-])=O)O.[Na+].[Na+].[Na+].O.Cl.N[C@H](C(O)=O)CS.C(O)[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.[Tc:48]([O-])(=O)(=O)=O.[Na+]>>[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[Tc+6:48]Participants
Procedure
The kit includes a lyophilized mixture of a copper complex of MIBI (tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate ([Cu(MIBI)4]BF4)) as the active ingredient, sodium citrate dihydrate as a buffer, L-cysteine hydrochloride monohydrate as a stabilization aid, mannitol as a lyophilization aid, and stannous chloride dihydrate as a reducing agent. Prior to use, the lyophilized mixture is reconstituted with sodium pertechnetate (99mTc) and boiled to form technetium (99mTc) Sestamibi. The U.S. Pharmacopoeia (29th Ed.) requires that a mean of not less than 90% (corrected area percentage) of the total radioactivity is represented by 99mTc-Sestamibi, and a mean of not more than 5% (corrected area percentage) of the total radioactivity is present as 99mTc pentamibi dimethylvinyl isonitrile.
Sources & evidence
- ORD record
- ord-7836256d1ac14ee49b277cc2f5533549
- Source dataset
- uspto-grants-2009_07
- Patent number
- US07563920B2
Linked notes
Loading…